Bio-Path Holdings, Inc. announced that Tara Sadeghi has joined the company as Director of Clinical Operations. Reporting to Dr. Ulrich Mueller, Chief Operating Officer, Ms. Sadeghi will be responsible for all clinical activities surrounding the company's drug development programs. Ms. Sadeghi, was previously the Assistant Director of the Cord Blood Bank Regulatory and Quality Assurance office at The University of Texas M. D. Anderson Cancer Center.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.91 USD | -5.91% | -4.50% | -79.37% |
May. 15 | Transcript : Bio-Path Holdings, Inc., Q1 2024 Earnings Call, May 15, 2024 | |
Apr. 19 | Bio-Path Closes $1.2 Million Share Offering | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-79.37% | 2.99M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.35% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- BPTH Stock
- News Bio-Path Holdings, Inc.
- Bio-Path Holdings, Inc. Appoints Tara Sadeghi as Director of Clinical Operations